source
- EU regulator withdraws Amgen's Tavneos authorization over serious trial breachesEuropean regulators have withdrawn the marketing authorization for Amgen's rare disease drug Tavneos, citing serious breaches in the pivotal clinical trial. The EMA said study staff from ChemoCent…
- Skye and Redx form new entity with $125M to advance fibrosis assetsSkye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…Fierce Biotech · 6h ago↗ source